Ranolazine , ≥99% , 95635-55-5

Synonym(s):
(±)-N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-ylacetamide;(±)-4-[2-Hydroxy-3-(o-methoxyphenoxy)propyl]-1-piperazineaceto-2′,6′-xylidide

CAS NO.：95635-55-5

Empirical Formula: C24H33N3O4

Molecular Weight: 427.54

MDL number: MFCD00864690

EINECS: 620-450-7

PRODUCT Properties

• Melting point: 119-1200C
• Boiling point: 624.1±55.0 °C(Predicted)
• Density: 1.174±0.06 g/cm3(Predicted)
• storage temp.: Sealed in dry,Room Temperature
• solubility: DMSO (Slightly), Methanol (Slightly)
• form: Solid
• pka: 14.06±0.20(Predicted)
• color: White
• CAS DataBase Reference: 95635-55-5(CAS DataBase Reference)

Description and Uses

Ranolazine is an orally available, extended release drug for the treatment of chronic angina in patients who have failed to respond to prior angina therapy. Chronic stable angina (CSA) is a common symptom of coronary artery disease wherein plaques in the coronary vasculature restrict blood flow to the heart, which in turn leads to insufficient oxygenation of the heart, typically during physical exertion or emotional stress. A vast majority of the existing anti-anginal and anti-ischemic therapies aim to correct the imbalance between myocardial oxygen demand and supply through mechanisms that produce reductions in heart rate or blood pressure.

antianginal, antiischemic

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P264-P270-P301+P312-P330-P501
• HS Code: 2933595960
• Hazardous Substances Data: 95635-55-5(Hazardous Substances Data)